GENMAB A/S -SP ADR (GMAB) Stock Fundamental Analysis

NASDAQ:GMAB • US3723032062

29.44 USD
+0.2 (+0.68%)
At close: Feb 27, 2026
29.44 USD
0 (0%)
After Hours: 2/27/2026, 8:07:18 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

GMAB gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 520 industry peers in the Biotechnology industry. GMAB gets an excellent profitability rating and is at the same time showing great financial health properties. GMAB has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year GMAB was profitable.
  • In the past year GMAB had a positive cash flow from operations.
  • Of the past 5 years GMAB 4 years were profitable.
  • Of the past 5 years GMAB 4 years had a positive operating cash flow.
GMAB Yearly Net Income VS EBIT VS OCF VS FCFGMAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

1.2 Ratios

  • With an excellent Return On Assets value of 21.10%, GMAB belongs to the best of the industry, outperforming 97.51% of the companies in the same industry.
  • GMAB's Return On Equity of 25.76% is amongst the best of the industry. GMAB outperforms 96.74% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 17.11%, GMAB belongs to the top of the industry, outperforming 96.74% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for GMAB is below the industry average of 17.87%.
  • The last Return On Invested Capital (17.11%) for GMAB is above the 3 year average (15.20%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 21.1%
ROE 25.76%
ROIC 17.11%
ROA(3y)15.92%
ROA(5y)16.24%
ROE(3y)18.48%
ROE(5y)18.5%
ROIC(3y)15.2%
ROIC(5y)16.1%
GMAB Yearly ROA, ROE, ROICGMAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20 25

1.3 Margins

  • With an excellent Profit Margin value of 41.35%, GMAB belongs to the best of the industry, outperforming 97.70% of the companies in the same industry.
  • GMAB's Profit Margin has declined in the last couple of years.
  • With an excellent Operating Margin value of 36.85%, GMAB belongs to the best of the industry, outperforming 97.51% of the companies in the same industry.
  • In the last couple of years the Operating Margin of GMAB has declined.
  • GMAB has a Gross Margin of 94.27%. This is amongst the best in the industry. GMAB outperforms 95.02% of its industry peers.
  • GMAB's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 36.85%
PM (TTM) 41.35%
GM 94.27%
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
GMAB Yearly Profit, Operating, Gross MarginsGMAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), GMAB is creating value.
  • There is no outstanding debt for GMAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GMAB Yearly Shares OutstandingGMAB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
GMAB Yearly Total Debt VS Total AssetsGMAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

  • An Altman-Z score of 11.14 indicates that GMAB is not in any danger for bankruptcy at the moment.
  • GMAB has a better Altman-Z score (11.14) than 82.57% of its industry peers.
  • GMAB has a debt to FCF ratio of 0.12. This is a very positive value and a sign of high solvency as it would only need 0.12 years to pay back of all of its debts.
  • GMAB has a Debt to FCF ratio of 0.12. This is amongst the best in the industry. GMAB outperforms 95.79% of its industry peers.
  • A Debt/Equity ratio of 0.02 indicates that GMAB is not too dependend on debt financing.
  • GMAB's Debt to Equity ratio of 0.02 is in line compared to the rest of the industry. GMAB outperforms 44.06% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 0.12
Altman-Z 11.14
ROIC/WACC2.33
WACC7.34%
GMAB Yearly LT Debt VS Equity VS FCFGMAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

2.3 Liquidity

  • GMAB has a Current Ratio of 6.03. This indicates that GMAB is financially healthy and has no problem in meeting its short term obligations.
  • GMAB has a Current ratio of 6.03. This is in the better half of the industry: GMAB outperforms 62.84% of its industry peers.
  • GMAB has a Quick Ratio of 6.01. This indicates that GMAB is financially healthy and has no problem in meeting its short term obligations.
  • GMAB has a better Quick ratio (6.01) than 63.41% of its industry peers.
Industry RankSector Rank
Current Ratio 6.03
Quick Ratio 6.01
GMAB Yearly Current Assets VS Current LiabilitesGMAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The earnings per share for GMAB have decreased by -2.61% in the last year.
  • GMAB shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 9.47% yearly.
EPS 1Y (TTM)-2.61%
EPS 3Y13.49%
EPS 5Y9.47%
EPS Q2Q%-75.02%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%14.88%

3.2 Future

  • GMAB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.81% yearly.
  • GMAB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.25% yearly.
EPS Next Y-0.98%
EPS Next 2Y11%
EPS Next 3Y22.44%
EPS Next 5Y13.81%
Revenue Next Year14.34%
Revenue Next 2Y14.31%
Revenue Next 3Y15.21%
Revenue Next 5Y9.25%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
GMAB Yearly Revenue VS EstimatesGMAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
GMAB Yearly EPS VS EstimatesGMAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 17.12, the valuation of GMAB can be described as rather expensive.
  • Compared to the rest of the industry, the Price/Earnings ratio of GMAB indicates a rather cheap valuation: GMAB is cheaper than 94.83% of the companies listed in the same industry.
  • When comparing the Price/Earnings ratio of GMAB to the average of the S&P500 Index (27.07), we can say GMAB is valued slightly cheaper.
  • A Price/Forward Earnings ratio of 17.29 indicates a rather expensive valuation of GMAB.
  • Based on the Price/Forward Earnings ratio, GMAB is valued cheaply inside the industry as 94.06% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of GMAB to the average of the S&P500 Index (28.05), we can say GMAB is valued slightly cheaper.
Industry RankSector Rank
PE 17.12
Fwd PE 17.29
GMAB Price Earnings VS Forward Price EarningsGMAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of GMAB indicates a rather cheap valuation: GMAB is cheaper than 97.32% of the companies listed in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of GMAB indicates a rather cheap valuation: GMAB is cheaper than 96.74% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 15.07
EV/EBITDA 9.53
GMAB Per share dataGMAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

  • The decent profitability rating of GMAB may justify a higher PE ratio.
  • A more expensive valuation may be justified as GMAB's earnings are expected to grow with 22.44% in the coming years.
PEG (NY)N/A
PEG (5Y)1.81
EPS Next 2Y11%
EPS Next 3Y22.44%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • GMAB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GENMAB A/S -SP ADR

NASDAQ:GMAB (2/27/2026, 8:07:18 PM)

After market: 29.44 0 (0%)

29.44

+0.2 (+0.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-18
Earnings (Next)05-07
Inst Owners44.16%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap18.13B
Revenue(TTM)N/A
Net Income(TTM)1.48B
Analysts73.08
Price Target95.18 (223.3%)
Short Float %1.42%
Short Ratio5.15
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.75%
Min EPS beat(2)25.14%
Max EPS beat(2)36.36%
EPS beat(4)4
Avg EPS beat(4)61.45%
Min EPS beat(4)25.14%
Max EPS beat(4)134.67%
EPS beat(8)6
Avg EPS beat(8)30.99%
EPS beat(12)8
Avg EPS beat(12)16.81%
EPS beat(16)12
Avg EPS beat(16)30.22%
Revenue beat(2)1
Avg Revenue beat(2)-0.2%
Min Revenue beat(2)-1.49%
Max Revenue beat(2)1.09%
Revenue beat(4)2
Avg Revenue beat(4)-1.55%
Min Revenue beat(4)-7.66%
Max Revenue beat(4)1.87%
Revenue beat(8)6
Avg Revenue beat(8)300.02%
Revenue beat(12)10
Avg Revenue beat(12)350.69%
Revenue beat(16)14
Avg Revenue beat(16)264.87%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-8.29%
EPS NQ rev (3m)-8.47%
EPS NY rev (1m)0%
EPS NY rev (3m)7.53%
Revenue NQ rev (1m)19.73%
Revenue NQ rev (3m)19.17%
Revenue NY rev (1m)0.75%
Revenue NY rev (3m)0.7%
Valuation
Industry RankSector Rank
PE 17.12
Fwd PE 17.29
P/S 5.06
P/FCF 15.07
P/OCF 14.23
P/B 3.15
P/tB 4.97
EV/EBITDA 9.53
EPS(TTM)1.72
EY5.84%
EPS(NY)1.7
Fwd EY5.78%
FCF(TTM)1.95
FCFY6.64%
OCF(TTM)2.07
OCFY7.03%
SpS5.82
BVpS9.34
TBVpS5.92
PEG (NY)N/A
PEG (5Y)1.81
Graham Number19.01
Profitability
Industry RankSector Rank
ROA 21.1%
ROE 25.76%
ROCE 21.02%
ROIC 17.11%
ROICexc 37.46%
ROICexgc 140.29%
OM 36.85%
PM (TTM) 41.35%
GM 94.27%
FCFM 33.59%
ROA(3y)15.92%
ROA(5y)16.24%
ROE(3y)18.48%
ROE(5y)18.5%
ROIC(3y)15.2%
ROIC(5y)16.1%
ROICexc(3y)68.77%
ROICexc(5y)79.83%
ROICexgc(3y)104.16%
ROICexgc(5y)104.49%
ROCE(3y)18.68%
ROCE(5y)19.78%
ROICexgc growth 3Y22.66%
ROICexgc growth 5Y11.4%
ROICexc growth 3Y-22.7%
ROICexc growth 5Y-14.09%
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
F-Score7
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 0.12
Debt/EBITDA 0.09
Cap/Depr 106.94%
Cap/Sales 1.98%
Interest Coverage 243.04
Cash Conversion 91.92%
Profit Quality 81.24%
Current Ratio 6.03
Quick Ratio 6.01
Altman-Z 11.14
F-Score7
WACC7.34%
ROIC/WACC2.33
Cap/Depr(3y)96.21%
Cap/Depr(5y)101.76%
Cap/Sales(3y)1.96%
Cap/Sales(5y)2.38%
Profit Quality(3y)107.36%
Profit Quality(5y)103.53%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.61%
EPS 3Y13.49%
EPS 5Y9.47%
EPS Q2Q%-75.02%
EPS Next Y-0.98%
EPS Next 2Y11%
EPS Next 3Y22.44%
EPS Next 5Y13.81%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%14.88%
Revenue Next Year14.34%
Revenue Next 2Y14.31%
Revenue Next 3Y15.21%
Revenue Next 5Y9.25%
EBIT growth 1Y41.76%
EBIT growth 3Y29.8%
EBIT growth 5Y21.02%
EBIT Next Year55.58%
EBIT Next 3Y25.57%
EBIT Next 5Y19.44%
FCF growth 1Y46.62%
FCF growth 3Y51.06%
FCF growth 5Y42.84%
OCF growth 1Y44.68%
OCF growth 3Y47.08%
OCF growth 5Y41.48%

GENMAB A/S -SP ADR / GMAB FAQ

What is the ChartMill fundamental rating of GENMAB A/S -SP ADR (GMAB) stock?

ChartMill assigns a fundamental rating of 7 / 10 to GMAB.


What is the valuation status for GMAB stock?

ChartMill assigns a valuation rating of 6 / 10 to GENMAB A/S -SP ADR (GMAB). This can be considered as Fairly Valued.


Can you provide the profitability details for GENMAB A/S -SP ADR?

GENMAB A/S -SP ADR (GMAB) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for GMAB stock?

The Price/Earnings (PE) ratio for GENMAB A/S -SP ADR (GMAB) is 17.12 and the Price/Book (PB) ratio is 3.15.


Can you provide the financial health for GMAB stock?

The financial health rating of GENMAB A/S -SP ADR (GMAB) is 8 / 10.